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A PRoliferation-Inducing TNF Ligand
(APRIL) costimulates B-cell activation.
When overexpressed in mice, APRIL in-
duces B-cell neoplasia, reminiscent of
human B-cell chronic lymphoid leukemia
(B-CLL). We analyzed APRIL expression
in situ in human non-Hodgkin lympho-
mas. APRIL up-regulation was only ob-
served in high-grade B-cell lymphomas,
diffuse large B-cell lymphoma (DLBCL),
and Burkitt lymphoma (BL). Up-regulation
was seen in 46% and 20% of DLBCL and
BL, respectively. In DLBCL, neutrophils,
constitutively producing APRIL and infil-
trating the tumor tissue, were the main
cellular source of APRIL. Rare DLBCL
cases showed a predominance of histio-
cytes or mesenchymal cells as APRIL
source. APRIL secreted by neutrophils
accumulated on tumor cells via proteogly-
can binding. In addition to proteoglycans,
DLBCL tumor cells expressed the APRIL
signaling receptor, TACI and/or BCMA,
indicating that these tumor cells are fully
equipped to respond to APRIL. A retro-
spective clinical analysis revealed a sig-
nificant correlation between high expres-
sion of APRIL in tumor lesions and
decreased overall patient survival rate.
Hence, APRIL produced by inflammatory
cells infiltrating lymphoma lesions may
increase tumor aggressiveness and af-
fect disease outcome. (Blood. 2007;109:
331-338)
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Introduction
Non-Hodgkin B-cell lymphomas (NHLs) are divided into 3
prognostic groups designated low-, intermediate-, and high-
grade B-cell lymphomas based on survival statistics, with
high-grade B-cell lymphomas harboring the worse prognosis.
High-grade lymphomas arising from mature B cells are consti-
tuted by Burkitt lymphoma (BL) and diffuse large B-cell
lymphoma (DLBCL). The latter represents the most common
form of adult NHL. DLBCL is widely accepted for its heteroge-
neity, best reflected by differences in clinical responses to
chemotherapy.1 DLBCL heterogeneity was recently molecularly
identified with gene-expression array studies.2 Despite the
significant improvement achieved in the therapy of this disease
with the emergence of B-cell–specific (anti-CD20) monoclonal
antibody treatment, resistant DLBCL remain a significant clini-
cal problem. Indeed, the recent report analyzing the effect of
chemotherapy combined with anti-CD20 indicates that 40% of
patients do not survive in a 5-year follow-up period.3 Future
improvements to DLBCL therapy are therefore likely to result
from the identification of key molecular targets in the treatment-
resistant subtypes.
APRIL (also known as TALL-2) and BAFF (also known as
BLys, TALL-1) are closely related ligands of the TNF superfam-
ily. They share 2 receptors, BCMA and TACI, whereas BAFF
binds to a third receptor BAFF-R (also known as BR3).4
BAFF-R, TACI, and BCMA are predominantly expressed on B
cells, consistent with a role for these 2 TNF ligands in humoral
immune responses. The BAFF/BAFF-R pathway is crucial
for the maturation and maintenance of peripheral B cells.5,6
BAFF participates also in humoral immune responses by
providing B-cell costimulation and inducing Ig switch.7,8 APRIL
has no obvious role in B-cell development9 but, like BAFF, is
involved in humoral immune responses.7,8,10 Dysregulation of
the BAFF/APRIL pathways has been associated with several
autoimmune diseases.11
In addition to a role in autoimmune pathologies, APRIL and
BAFF have been recently implicated in the development of
tumors.12 In animal models, APRIL and BAFF overexpression
induces development of B-cell neoplasia.13,14 The involvement of
these 2 TNF ligands in B-cell tumors has been substantiated with in
vitro studies on human cell lines. Exogenous APRIL confers a
survival advantage to NHL,15-17 and multiple myeloma.18-20 Re-
cently, APRIL binding to the heparan sulfate side chains of
proteoglycans (HSPG) was demonstrated.21,22 In contrast, BAFF
does not bind HSPG, suggesting differences in APRIL and BAFF
biology. Here, we analyzed in situ APRIL expression in human
NHL. We observed that APRIL was only up-regulated in high-
grade B-cell lymphomas and found that proteoglycans contribute to
a tumor-promoting role of APRIL in these lymphomas.
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Patients, materials, and methods
Cells and reagents
All culture media were RPMI-1640 supplemented with 10% FCS. The
DLBCL lines SU-DHL-4 and -7 and OCI-Ly3, OCI-Ly7, and OCI-Ly10
were obtained from Dr A. Wiestner (NIH, Bethesda, MD). Dendritic cells
were obtained from peripheral monocytes treated with GM-CSF/IL-4 as
previously described.23 Granulocytes were obtained from bone marrow
CD34 cells as previously reported.24 Polymorphonuclear cells (PMNs)
were isolated from healthy donors. Briefly, blood was collected on sodium
citrate (3.8%). Red blood cells were removed by sedimentation on PBS
Dextran T500, and floating cells were further separated by centrifugation on
a layer of Ficoll-Hypaque. Pelleted cells were PMNs, whereas layered cells
were peripheral-blood mononuclear cells (PBMCs). To avoid PMN activa-
tion, all separation steps were performed at 4°C in the presence of 5 g/mL
Polymixin B. Heparin (Liquemin, 5000 IU/mL) was from Roche Pharma
(Basel, Switzerland). Anti-TACI (clone 1A1, rat IgG2a,), anti-BCMA
(clone Vicky1, rat IgG2a), anti-APRIL against the extracellular portion
(93-233) of APRIL (clones Aprily-1, -2, -4, -5, -6, -8, all mouse IgG1), and
pAb ED (rabbit polyclonal against the aa 67-79 peptide GTGGPSQNG-
EGYP of APRIL), called Stalk-1 hereafter, were obtained from Alexis
Biochemicals (Basel, Switzerland). An antiserum against the same extracel-
lular portion (88-233) of APRIL was made in rabbit and used for detection
in enzyme-linked immunoabsorbent assay (ELISA). MegaAPRIL consist-
ing of extracellular APRIL (88-233) fused to ACRP30 (16-108), its control
headless ACRP30, hereafter-called acrpAPRIL and acrpCTRL, respec-
tively, were also from Alexis Biochemicals. Anti-CD15 (clone C3D-1,
IgM), antielastase (clone NP57, IgG1), anti-CD20 (clone L26, IgG2a),
anti–bcl-6 (clone PG-B6P, IgG1), anti–Ki-67 (clone MIB-1, IgG1), antivi-
mentin (clone V9, IgG1), anti-CD68 (clones PGM-1 and KP1), and anti–L1
protein (clone Mac 387, IgG1) antibodies were from Dako (Glostrup,
Denmark). Anti-CD10 (clone 56C6, IgG1) was from Novacastra (New-
castle upon Tyne, United Kingdom). Anti–IRF-4 (goat polyclonal) and
anti–syndecan-4 (rabbit polyclonal) were from Santa Cruz Biotechnology
(Santa Cruz, CA). The anti-CD10 used to stain bone marrow granulocytes
in flow cytometry was from Pharmingen (San Diego, CA). Expression
vectors for Flag ligands and receptors fused to the cartilage outer membrane
protein (COMP) have been previously described.25,26 An APRIL bearing the
mutation RR103-104 to AA was created by polymerase chain reaction
(PCR)–assisted mutation. Flag-tagged huAPRILA88 (88-233) and BCMA-
COMP were produced by transiently transfected 293T cells in serum-free
optimem (Gibco BRL, Rockville, MD) and purified by M2-Sepharose
affinity chromatography (Sigma, St Louis, MO).
Flow cytometry
Cell staining was performed as previously described.23 Antibody staining
was revealed with a secondary Alexa-488–conjugated goat anti–mouse or
anti–rabbit serum (Molecular Probes, Leiden, The Netherlands). Ligand
staining was revealed with an anti-Flag antibody (IgG1, Clone M2; Sigma)
at 5 g/mL and phycoerythrin-conjugated goat-anti–mouse IgG1 (Jackson
Immunoresearch, Baltimore, PA). For total staining, cells were fixed/
permeabilized with PBS 1% formaldehyde, and staining was performed in
the presence of 1% saponin.
Detection of secreted APRIL
For APRIL quantification in sera, BCMA-Ig 1 g/mL (Alexis Biochemi-
cals) was used as capture, and detection was performed with a homemade
rabbit polyclonal anti-huAPRIL (1 g/mL), followed by an HRP-
conjugated goat anti–rabbit IgG serum (Jackson Immunoresearch). Tetra-
methylbenzidine (Sigma) was used as substrate for HRP. Sensitivity of this
ELISA was 1 to 3 ng/mL.
For APRIL detection in cell supernatants, secreted APRIL was immuno-
precipitated with BCMA-Ig and detected in Western blot with the Aprily-1
mAb as previously described.23 Supernatant (5 mL) was conditioned by
50  106 neutrophils pooled from 5 donors in the presence of 1000 IU/mL
G-CSF (kind gift of V. Kindler, Geneva, Switzerland) for 48 hours. Control
supernatant was conditioned by 50  106 PBMCs from a single donor.
Gene-expression analysis
Total RNA (25 ng) prepared from cells using TRIzol Reagent (Gibco BRL)
was reverse transcribed and amplified using a one-step reverse transcriptase
(RT)–PCR kit (Qiagen, Chatsworth, CA). All the primers used in this study
spanned intronic sequences on the genomic DNA. For hTACI 5-
ctgggtacctgcatgtcctg-3and 5-agacttggccggactttgac-3, for hBCMA 5-
gggcagtgctcccaaaat-3 and 5-tcgttttcgtggtgacaaga-3, and for hAPRIL
5-atgccagcctcatctccttt-3 and 5-tcctggattcggacaccata-3 were used as
forward and reverse primers, respectively. The control actin primers were
forward 5-ttaacgagaagctgtgctacgtc-3 and reverse 5-atagtcctgcttgcttgctgatc-
cac-3. Amplicon specificity was ascertained by restriction analysis with 3
selected enzymes for each primer pair.
Immunohistochemistry
For immunocellularchemistry (ICC), cells were injected into murine intestine.
The injected intestines were fixed and embedded into paraffin. The resulting
blocks were then treated as a standard tissue for immunostaining.
Patient’s diagnosis was made according to the World Health Organiza-
tion classification. Tissue microarrays were constructed as previously
described.27 For immunoperoxidase staining, secondary reagents were goat
Ig anti–rabbit or anti–mouse IgG conjugated to HRP (Jackson Immunore-
search), followed by streptABComplex/HRP (Dako) and 3-amino-9-
ethylcarbazole substrate (Sigma). For 2-color immunofluorescence stain-
ings, isotype-specific goat antimouse sera conjugated to biotin or
phycoerythrin (Jackson Immunoresearch) and goat Ig anti–rabbit IgG
conjugated to Alexa-488 (Molecular Probes) were used. For light and
fluorescence microscopy, mounting media were aquatex (Merck, Glattbrugg-
Opfikon, Switzerland) and 12% Molwiol 4-88, 30% glycerol in 0.2 M Tris,
pH 8.5. Light and fluorescence microscopy images were visualized with an
Axiophot I microscope (Carl Zeiss, Jena, Germany) equipped with one of
the following: a Plan Neofluar 63 /1.25 oil-immersion objective lens
(Figures 2 and 3I), a Plan Neofluar 100 /1.30 oil-immersion objective lens
(Figure 3E-H), or a Plan Neofluar 40 /0.75 air objective (Figures 3A-D
and 5A-C). Images were captured with an Axiocam color CCD camera and
were treated on a Pentium III computer with Axiovision software (Carl
Zeiss). Confocal analysis was performed on an LSM 510 microscope (Carl
Zeiss) equipped with a Plan Neofluar 40 /1.30 oil-immersion objective
lens (Figure 3J).
Patient follow-up and statistical analysis
All patients with a diagnosed DLBCL were seen, and their specimen was
obtained between 1995 and 2003 at the Geneva University Hospital.
Retrospective study of the clinical data from these patients was performed.
Patients provided written informed consent in accordance with the Declara-
tion of Helsinki. The project was reviewed and approved by the Geneva
University Hospital Ethics Committee. Survival was measured from the
date of biopsy until the date of death from lymphoma, excluding comorbid-
ity. Patients alive at the last follow-up evaluation were censored (tickles on
the curves). Kaplan-Meier overall survival curve was performed with Prism
software (GraphPad Software, San Diego, CA). Comparison between
groups was based on a log-rank statistical test.
Results
Characterization of antibodies selectively recognizing secreted
APRIL and APRIL-producing cells
To study in situ APRIL expression, APRIL-specific antibodies with
different specificities were selected. The mAb Aprily-2 was raised
against the c-terminal TNF homology domain of APRIL, secreted
on furin cleavage. The polyclonal rabbit antiserum Stalk-1 was
raised against a peptide in the membrane-proximal part of APRIL
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extracellular domain remaining associated to the cell membrane
after furin cleavage. This domain is called the APRIL Stalk
hereafter. Selective stainings on transfected cells overexpressing
APRIL were obtained with these antibodies (Figure S1A, available
on the Blood website; see the Supplemental Figures link at the top
of the online article). As described below, Stalk-1 and Aprily-2
generated positive staining by immunohistochemistry (IHC) on
DLBCL lesions (Figure 1). The protein products detected by
Stalk-1 and Aprily-2 were biochemically characterized from
lysates of these tumor lesions. Western blot analysis showed that
Aprily-2 identified a predominant 18-kDa band in IHC-positive
lesions, whereas no such band was observed in IHC-negative
lesions (Figure 2A, left). The 18-kDa band recognized by
Aprily-2 is compatible with the size of secreted APRIL that we
previously described in the supernatant of dendritic cells.23
Notably, the full-length molecule (30 kDa) was not detected in
lesions. This absence of detection was not due to a failure of
Aprily-2 to recognize full-length APRIL, because Aprily-2
stained 293T transfected cells expressing an uncleaved mutant
of APRIL in ICC (Figure S1B). In contrast, Stalk-1 recognizes a
14-kDa band selectively in IHC-positive lesions (Figure 2A,
middle), compatible with the predicted size of the APRIL stalk
domain after cleavage. This cleaved product is also observed as
a predominant band in dendritic-cell (DC) lysates (Figure 2A,
right). Specificity of the Abs was further assessed in competition
experiments. Addition of soluble APRIL or stalk peptide to the
respective antibodies prior to Western blot analysis abolished
the recognition of the 18-kDa and 14-kDa bands, respectively
(Figure 2B), demonstrating that the molecular species recog-
nized in Western blot expressed the relevant epitopes. The
combined absence of detection of the full-length product by
these 2 antibodies shows that most of APRIL is rapidly cleaved
and secreted after synthesis in APRIL-producing cells. This
observation is consistent with the early APRIL processing in the
secretory pathway described previously.28 It also indicates that
the stalk of cleaved APRIL remains stable in APRIL-producing
cells, making Stalk-1 a valuable tool to detect APRIL-producing
cells, whereas Aprily-2 detects secreted APRIL.
Strong up-regulation of APRIL in DLBCL lesions
The Aprily-2 mAb was used to stain multitumor arrays prepared
from NHL lesions and control healthy tissues. Among the DLBCLs
analyzed (n  56), 46% were strongly positive for secreted APRIL
(Aprily-2 staining) (Figure 1, top). The remaining DLBCL cases
showed only a focal staining pattern. The APRIL up-regulation was
also seen in BL lesions (2 of 10). In contrast, all the lesions from
low to intermediate NHL revealed only focally distributed stained
cells with large areas of unstained cells as shown in Figure 1
(bottom). This was the case with mucosa-associated lymphoid
tissue (n  18), follicular-cell (n  35), mantle-cell (n  5), and
marginal-zone (n  6) lymphomas, as well as nodular chronic
lymphocytic leukemia (n  14). In a substantial proportion of these
lesions, Aprily-2 staining was even undetectable. In DLBCL,
lesions harboring a strong staining for secreted APRIL also
contained abundant cells producing APRIL (Stalk-1 staining)
(Figure 1, top). Hence, detection of secreted APRIL correlated with
the presence of APRIL-producing cells in the lesions. Detailed
analysis of the staining patterns revealed dissimilarity between
Aprily-2 and Stalk-1. Although some Aprily-2 staining appears not
to be associated to any cell, a majority of the staining was
concentrated on cells with a morphology reminiscent of DLBCL.
The punctuated Aprily-2 staining was also observed with 2 other
mAbs raised against secreted APRIL (Aprily-6 and Aprily-8) (data
not shown). In contrast, Stalk-1 produced a staining associated to
cells with an apparent different morphology. In this experiment,
Aprily-2 and Stalk-1 tissue staining was competed with soluble
APRIL and stalk peptide, respectively, further demonstrating
specificity (data not shown). Taken together, this IHC analysis
indicates that APRIL expression is markedly up-regulated in some
high-grade NHL lymphomas, such as DLBCL and BL, but not in
lower grade NHLs. Once secreted, cleaved APRIL dissociates from
APRIL-producing cells.
Tumor-infiltrating neutrophils produce APRIL
We next identified APRIL-producing cells in situ with 2 color
immunofluorescence stainings on whole tumor sections. In 19 of 25
Figure 2. Characterization of anti-APRIL antibodies identifying secreted APRIL and
cells producing APRIL. (A) Extracts (20 g) from IHC-positive and -negative
DLBCL tissue samples were analyzed by Western blot with Aprily-2 (2 g/mL)
and Stalk-1 (5 g/mL). An 18-kDa band corresponding to secreted APRIL was
revealed with Aprily-2 (left), whereas Stalk-1 identified a 14-kDa band (middle).
Similar 14-kDa reactivity was observed with Stalk-1 on DC lysates (20 g)
(right). The reactivity is representative of 3 IHC-positive and 2 IHC-negative tumor
lysates. (B) Western blot specificity was ascertained in blocking experiments.
Aprily-2 was preincubated with 10 g/mL acrpAPRIL or acrpCTRL. Stalk-1
was preincubated with 10 g/mL stalk peptide or an irrelevant peptide prior to
Western blot analysis.
Figure 1. APRIL is strongly expressed in DLBCL lesions. DLBCL tumor lesions
were stained with Aprily-2 (left) and Stalk-1 (right). Representative tumor lesions with
high (top) and low (bottom) expression of APRIL are shown. Original magnification
was  63. Concentration of the Aprily-2 staining on cells with a morphology
reminiscent of DLBCL was marked with an arrow.
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of the patients with DLBCL analyzed, greater than 60% of
Stalk-1–positive cells expressed CD15, identifying them as granu-
locytes (Figure 3A). Their precise neutrophil identity was obtained
by finding that they expressed elastase, a neutrophil-specific
protease (Figure 3B) and by their characteristic nuclear morphol-
ogy (Figure 3E). The neutrophil identity was confirmed because no
eosinophil (eosin staining) or basophil (IgE staining) was detected
in these lesions (data not shown). In the other patients, the
Stalk-1–positive cells were histiocytes expressing the L1 protein (2
of 25; Figure 3C) or mesenchymal cells expressing vimentin (4 of
25; Figure 3D). L1-protein or vimentin-expressing cells observed
here did not express CD68, excluding them from bona fide
tumor-infiltrating macrophages (data not shown). In this experi-
ment, we noticed that the intensity of the Stalk-1 staining in IHC
was higher in neutrophils than in histiocytes and mesenchymal
cells present in the same section (Figure 3F-H). Finally, we also
observed few endothelial cells, lining vessels draining the tumor,
also stained with Stalk-1 (Figure 3I). All CD15 (or elastase) and
L1 protein cells were stained with Stalk-1 (Figure 3A-C),
indicative of a constitutive APRIL expression in neutrophils and
histiocytes from DLBCL lesions. This was not the case for
mesenchymal cells, because vimentin Stalk-1 cells were ob-
served (Figure 3D). Taken together, this indicates that the cellular
source of APRIL in DLBCL lesions is disparate, but neutrophils
were the main source of APRIL. This was due to their abundant
presence and their high level of APRIL production. As a conse-
quence, DLBCL cases with APRIL up-regulation (Stalk-1 and
Aprily-2 staining) correlated with high numbers of neutrophils.
There was only one exception, that of a case containing histiocytes
and harboring APRIL up-regulation. The other “histiocytic” case
and the “mesenchymal” cases were low in APRIL expression.
CD20 staining, used here as a DLBCL marker, was combined to
Stalk-1 staining to localize APRIL-producing neutrophils in the
lesions. Figure 3J shows that APRIL-producing cells were located
close to tumor cells. APRIL-producing neutrophils were also
observed inside (Figure 3I) or close to vessels (data not shown),
indicating an extra vasation from blood vessels draining the tumor.
To further characterize APRIL expression, neutrophils from
healthy volunteers were studied. In this experiment, availability of
fresh cells allowed us to confirm APRIL mRNA expression by
circulating neutrophils (Figure 4A). APRIL protein was detected in
isolated peripheral-blood neutrophils by ICC and in bone marrow
resident cells with a morphology consistent with granulocytes by
IHC (Figure S2). The reactivity was similar to in situ IHC with an
absence of reactivity for Aprily-2 on Stalk-1 cells. APRIL protein
expression in neutrophils was further studied by flow cytometry.
Stalk-1 stained peripheral-blood and bone marrow CD10 granulo-
cytes after cell permeabilization (Figure 4B-C). No staining was
observed with Aprily-2 in this assay. However, 3 independent
mAbs (Aprily-4, -5, -8), also directed against the secreted domain,
gave a staining (Figure 4B). The staining was weak, explaining the
absence of detection in APRIL-producing cells by IHC or ICC. In
contrast, there was no detectable staining at the cell surface with
Stalk-1 or Aprily-4, -5, or -8 by flow cytometry. Interestingly, we
observed that APRIL expression was induced early in the differen-
tiation of granulocytes, because the major fraction of high forward
scatter CD10 cells, representing immature cells,29 was also
stained with Stalk-1 (Figure 4C, bottom). There was no reactivity
Figure 4. APRIL production by neutrophils is constitutive. (A) APRIL expression
in peripheral neutrophils was observed at the gene-expression level by RT-PCR
analysis. DC and T cells were used as positive and negative controls, respectively.
(B) Total staining after cell permeabilization or surface staining was performed with
Stalk-1 (2 g/mL) and Aprily-8 (1 g/mL) Abs. Histogram plots after flow cytometry
analysis are shown. Thick and thin lines correspond to indicated Abs and isotype-
matched control Abs, respectively. Stainings are representative of 4 donors. (C) Bone
marrow cellular suspensions were stained with Stalk-1 and anti-CD10 Abs. Histo-
gram plots after flow cytometry analysis are shown on CD10 and CD10 size-gated
granulocytes (right). Thick and thin lines correspond to Stalk-1 and isotype-matched
control Abs, respectively. Stainings are representative of 3 donors. (D) Supernatants
conditioned by PMNs and PBMCs were immunoprecipitated with BCMA-Ig and
analyzed by Western blot with the Aprily-1 mAb.
Figure 3. APRIL is produced mainly by neutrophils infiltrating DLBCL lesions.
Stalk-1 staining (green) was combined to (A) anti-CD15 (1 of 50), (B) antielastase
(1 g/mL), (C) anti-L1 protein (10 g/mL), and (D) antivimentin (5 g/mL) stainings
(all in red). Single stainings and corresponding merge pictures shown are representa-
tive of 2 or more patients with DLBCL. (E) Morphology of Stalk-1–stained cells. (F-H)
Intensity of Stalk-1 staining is shown for a cell with a morphology of (F) a neutrophil,
(G) a histiocyte, and (H) a mesenchymal cell from the same lesion. The pictures were
taken with the same exposure time. (I) The picture shows endothelial cells lining
tumor-draining vessels (arrow) and blood neutrophils stained with Stalk-1.(J) Stalk-1
staining (green) was combined to anti-CD20 staining (red, 5 g/mL) and analyzed by
confocal microscopy. Single stainings and corresponding merge picture are represen-
tative of 6 patients with DLBCL.
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on peripheral blood and bone marrow mononuclear cells, indicat-
ing that neutrophils were also the main source of APRIL in healthy
tissues. Taken together, these analyses confirm the rapid APRIL
processing, rendering the secreted domain of APRIL barely detect-
able in producing cells. In fact, the secreted domain was only
detected in producing cells when APRIL was overexpressed (see
Figure S1). They further indicate that the Stalk domain locates in
the cytoplasm after APRIL processing. The precise cellular localiza-
tion of the Stalk domain was analyzed by confocal microscopy.
Costaining in granulocytes with Stalk-1 and CD15, a marker
expressed at the cell membrane and into cytoplasmic granules,30
revealed that only a minor fraction of the Stalk domain was
expressed at the cell surface. Most of it was observed diffusely in
the cytoplasm (Figure S3, top). This distribution was confirmed by
colocalization of Stalk-1 and the L1 protein, a marker expressed in
the cytoplasm of histiocytes31 (Figure S3, bottom). We next tried to
detect secreted APRIL. APRIL secretion was only detected in the
supernatant of G-CSF–stimulated cells by immunoprecipitation
followed by Western blot revelation (Figure 4D). The faint band
observed gave an in vitro secretion estimate of less than 100
pg/mL/10  10e6 cells/48 hours in this experiment. This weak
secretion level explained our failure to detect secreted APRIL by
sandwich ELISA (sensitivity ranging between 1 and 3 ng/mL; data
not shown). In conclusion, APRIL expression is induced early
during neutrophil differentiation and sustained in mature neutro-
phils present in the bone marrow and circulating in peripheral
blood. The level of expression between these latter cells and
tumor-infiltrating neutrophils appears similar by IHC, indicating
that APRIL expression by neutrophils is mainly constitutive.
Proteoglycans ensure APRIL retention in lesions and binding
onto tumor cells
APRIL was recently shown to interact with cell-surface HSPG.21,22
We therefore assessed HSPG expression in DLBCL lesions. We
observed expression of syndecan-4 in some of the DLBCL cases
analyzed, consistent with the fraction of DLBCLs expressing
syndecan-4 mRNA.32 Remarkably, secreted APRIL is strictly
located at syndecan-4 expression sites in the tumor lesions
expressing this HSPG (Figure 5A). Such an overlap is strongly
suggestive of a tight interaction of APRIL with syndecan-4 in situ.
In the other DLBCL cases, syndecan-4 was not expressed, but the
Aprily-2 staining observed was identical, with characteristic punc-
tuation, indicative of an association with HSPG from other(s)
proteoglycan(s). Combination of CD20 and syndecan-4 staining
showed that tumor cells homogeneously expressed syndecan-4 in
this lesion, with a major pool expressed intracellularly compared
with the CD20 membrane staining (Figure 5B). Finally, combina-
tion of CD20 and Aprily-2 showed that some of the tumor cells
bound secreted APRIL, with also a major intracellular pool (Figure
5C). These analyses show that APRIL, once secreted by neutro-
phils, binds to the tumor cell via an interaction with HSPG.
We next tested APRIL up-regulation in the circulation. Sera
from patients with “high APRIL expressor” DLBCL (n  5) were
tested for the presence of APRIL by ELISA. Circulating APRIL
was not detected in these patients, indicating a concentration below
1 ng/mL, whereas it was detected in sera from autoimmune patients
with lupus erythrematosus (30 ng/mL; data not shown), as previ-
ously reported.11 The up-regulation of APRIL is therefore local in
DLBCL and does not reach the circulation, likely because of
retention by proteoglycans in the tumor lesion.
DLBCL tumor cells express BCMA and TACI in addition
to proteoglycan
We next assessed the expression of BCMA and TACI in DLBCL.
Despite tests with several reactive antibodies, endogenous BCMA
or TACI was not detected in situ in DLBCL tumor lesions, probably
reflecting a low level of endogenous expression (data not shown).
We therefore used DLBCL cell lines to assess APRIL receptor
expression in tumor cells. RT-PCR analysis showed TACI and
BCMA mRNA expression in 2 of 5 and all DLBCL cell lines,
respectively (Figure 6A). In this experiment, we confirmed that
DLBCLs do not express APRIL at the mRNA level compared with
myeloid cells such as DCs, because an APRIL band was observed
in DCs but not in DLBCLs even after 35 RT-PCR cycles.
Anti-TACI and BCMA were next used. The specificity of these
mAbs was first validated on transfected cells (Figure 6B). TACI
protein expression at the cell surface was confirmed in the 2
DLBCL cell lines positive for TACI mRNA but not in the other
lines. In contrast, expression of surface BCMA was barely detect-
able, but significant staining was observed after cell permeabiliza-
tion in 3 of 5 DLBCL cell lines. The level of intracellular BCMA
for the 2 other cell lines was weaker. Binding of soluble APRIL was
next tested. Heparin and soluble BCMA were used to compete
APRIL/HSPG and APRIL/TACI BCMA interactions as previously
described.21 Soluble APRIL bound homogeneously to all DLBCL
cell lines. However, the level of inhibition with heparin and soluble
BCMA varied. Complete and absence of inhibition was observed
on cell lines negative for TACI with heparin and BCMA, respec-
tively, indicating that HSPG was the unique APRIL-R on the
surface of these cells. In contrast, partial inhibition was seen with
heparin and BCMA on the TACI-expressing cell lines, indicating
that both TACI and HSPG were expressed as APRIL-R on the
surface on these cells. Figure 6C shows APRIL receptor expression
for the 2 representative cell lines OCI-Ly3 and OCI-Ly7. Two
phenotypes for DLBCLs therefore exist regarding APRIL receptor
expression, TACIsurfBCMAintlowHSPGsurf and TACIsurf-
BCMAintHSPGsurf. HSPG expression in association with TACI
and/or BCMA expression was also observed in the BL cell lines
Namalwa, Ramos and BL41 (data not shown). As previously
reported by He et al,16 we also observed a survival signal in vitro
Figure 5. APRIL is concentrated on tumor cells by proteoglycans. (A) DLBCL
lesions were stained with anti–syndecan-4 (green, 10 g/mL) and Aprily-2 (red), (B)
with anti–syndecan-4 (green) and anti-CD20 (red), and (C) with anti-CD20 (green)
and Aprily-2 (red). Single stainings and the corresponding merge picture are
representative of 4 patients.
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for DLBCL with exogenous ACRP-APRIL (data not shown).
Hence, DLBCLs are fully equipped to respond to APRIL signaling.
High APRIL expression in tumor lesions of patients with
DLBCL is associated with a reduced survival rate
The role of APRIL in DLBCL was assessed by a retrospective
clinical analysis of the patients analyzed here for APRIL expression
in biopsy samples. Data on stage and LDH levels were available for
a limited number of patients. High and low levels of APRIL could
be observed for different stages and LDH expression (Table 1).
There were also no significant differences between high and low
APRIL expressors in terms of tumor proliferation index and age. In
addition, low and high levels of APRIL expression were observed
in the 2 DLBCL subtypes, germinal center and activated, indicating
no obvious correlation between levels of APRIL expression and
standard clinical parameters at the time of diagnosis. We next
analyzed the survival rate. Of the 39 patients analyzed for APRIL
expression, 34 had trackable survival data. Interestingly, a signifi-
cant decrease (P  .02) in survival was observed in the high
APRIL expressor group (Figure 7). The survival rate at 5 years was
50% and 80% for the patients with high and low expression,
respectively. This latter observation indicates that APRIL has a
tumor-promoting role in DLBCL.
Discussion
We have analyzed APRIL expression in human NHL in situ with
specific antibodies allowing identification of APRIL-producing
cells, as well as localization of secreted APRIL. We found high
numbers of APRIL-producing cells and increased levels of secreted
APRIL in about 50% and 20% of the DLBCL and BL cases
analyzed, respectively. There was no APRIL up-regulation for
lower grade B-cell lymphomas. Our analysis at the protein-
expression level is in full accordance with the up-regulation of
APRIL gene expression selectively observed in a fraction of
DLBCLs by Alizadeh et al.33 The cellular source of APRIL in
DLBCL lesions was disparate. However, in all the lesions showing
APRIL up-regulation, the main source of APRIL was neutrophils.
Only one case, likely to be histiocyte-rich DLBCL,34 contained a
majority of histiocytes. We could not detect tumor cells expressing
APRIL. This shows that APRIL expression in tumor cells, reported
previously in vitro,16 is low compared with in situ neutrophils. The
APRIL production by inflammatory cells in B-cell lymphomas
likely explains the selective APRIL up-regulation in high-grade
B-cell lymphoma lesions, compared with lower grade B-cell
lymphoma/leukemia known to develop with a less pronounced
host-cell infiltration.
Secreted APRIL was found associated to tumor cells. This
localization was ensured by HSPG binding APRIL. The punctuated
APRIL/HSPG staining reflects proteoglycan clustering induced on
ligand binding.35 In addition, APRIL binding to HSPG appears to
induce proteoglycan internalization in vivo, because in situ staining
for syndecan-4 and secreted APRIL localizes inside the cells. Such
internalization of proteoglycan on ligand binding to HSPG has
already been described.36 Proteoglycan clustering and internaliza-
tion is likely to indicate an early response to APRIL in DLBCL.
HSPG expression by DLBCL tumor cells was confirmed in vitro on
cell lines. In addition to proteoglycans, DLBCL tumor cells
expressed uniformly BCMA, consistent with previous data.16
BCMA staining was low on intact DLBCL tumor cells but
significantly enhanced after permeabilization, confirming the pres-
ence of a major pool of BCMA in the Golgi apparatus.37 In addition
to BCMA, some DLBCL tumor cells express TACI, also consistent
with previous data.38 Hence, APRIL-R expression constitutes
another level of heterogeneity in DLBCL tumor cells. HSPG on
tumor cells is likely to serve as coreceptor, concentrating the ligand
Figure 6. DLBCL tumor cells express BCMA/TACI signaling receptor and
proteoglycan coreceptor. (A) RT-PCR analysis of TACI, BCMA, and APRIL
mRNA expression in DLBCL cell lines. (B) Specificity of the anti-TACI and BCMA
mAbs is shown on transfected 293T cells. (C) APRIL-R expression analysis by
flow cytometry. Control stainings (isotype control and acrpCTRL) are shown as
dotted lines. Heparin and BCMA-COMP were used at 1/100 and 50 g/mL,
respectively. SUDHL-4 and -7 harbored identical staining to OCI-Ly7. OCI-Ly10
harbored an identical staining to OCI-Ly3.
Table 1. Clinical data from patients with DLBCL
APRIL high APRIL low
Disease stage*
I, n 1 2
II, n 1 2
III/IV, n 4 4
Serum LDH level†
High, n 5 6
Low, n 3 2
Proliferation index‡, mean SD 75 8 (n 22) 68 19 (n 25)
DLBCL type§
GC, n 19 17
Activated, n 17 10
Age, y, mean SD 61 19 (n 26) 57 8 (n 30)
LDH indicates lactate dehydrogenase; GC, germinal center.
*Disease stage was defined according to the Ann Arbor staging system.
†Serum LDH level was determined by standard techniques.
‡The proliferation index was determined by Ki-67 in situ staining.
§The DLBCL type was defined in IHC with the combination of CD10, bcl-6, and
IRF-4 markers as reported recently by Hans et al.46
Figure 7. High APRIL expression in patients with DLBCL is associated with
decreased survival. Survival was retrospectively studied in patients stratified
according to APRIL expression.
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on tumor cells. This in situ ligand retention by proteoglycans is
efficient, because no circulating APRIL could be detected in the
sera of patients with high APRIL expression. Ligand retention may
not be the unique role of proteoglycans in APRIL biology. Indeed,
secreted APRIL, expected to be a trimer, does not costimulate B
cells, unless oligomerized by a crosslinking mAb.21 Multiplicity of
the binding site on heparan sulfate side chains of proteoglycans is
thus likely to mediate such oligomerization of secreted APRIL; this
phenomenon has been already reported for some growth factors.39
Furthermore, the contribution of HSPG to APRIL signaling may be
different, depending on the signaling receptor involved. HSPG, by
its capacity to internalize bound ligand, may serve to route APRIL
from the extracellular medium toward BCMA expressed in Golgi.
For TACI, a direct interaction with HSPG has been recently
reported.40 In this context, HSPG may form a tight trimolecular
complex with cell-surface TACI and APRIL to enhance signaling,
as already shown for FGF/FGF-R.41 At the present time, it is
difficult to state which APRIL signaling receptor is involved. Both
are expressed on DLBCL cells depending on the patients. BCMA
has been implicated in the survival of post–germinal center
plasmablasts.42 TACI, despite an early report showing a negative
signaling into B cells,43 plays also a role in the generation of
plasmablasts,44 confirmed by a positive signaling transmitted to B
cells.40 TACI and BCMA are therefore valid candidates, and the
specific issue of APRIL receptor(s) involvement in DLBCL
warrants further investigations.
Planelles et al13 elegantly showed that transgenic mice overex-
pressing APRIL in T cells develop B-cell chronic lymphocytic
leukemia (B-CLL)–like lymphoma. This study highlighted the
B-cell tumor-promoting role for APRIL in an animal model. We are
now showing a correlation between APRIL expression and aggres-
siveness of human NHL. However, the human situation is different.
In human lymphoma lesions, APRIL is mainly produced by
inflammatory neutrophils, and strong APRIL expression is re-
stricted to high-grade NHL (DLBCL and BL). The tumor-
promoting effect of APRIL observed here supports the currently
emerging concept that host inflammatory reactions contribute to
tumor development.45 APRIL may therefore represent a key
molecule in the development of high-grade B-cell lymphoma, in
addition to BAFF, also recently associated with NHL aggressive-
ness.38 Prognosis factors commonly used in DLBCL was recently
contested by the molecular characterization of DLBCL diversity in
gene-expression analyses.2 The correlation of APRIL expression
and lymphoma aggressiveness reported here indicates that APRIL
may be a newly identified biologic factor influencing the develop-
ment of DLBCL. Investigation with a larger cohort of patients is
definitely warranted to assess whether APRIL is able to modulate
independently DLBCL development.
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